2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population

Ming Lung Yu*, Pei Jer Chen, Chia Yen Dai, Tsung Hui Hu, Chung Feng Huang, Yi Hsiang Huang, Chao Hung Hung, Chun Yen Lin, Chen Hua Liu, Chun Jen Liu, Cheng Yuan Peng, Han Chieh Lin, Jia Horng Kao, Wan Long Chuang

*此作品的通信作者

研究成果: Article同行評審

39 引文 斯高帕斯(Scopus)

摘要

Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy, excellent safety profile, and truncated treatment duration, has revolutionized the paradigm of hepatitis C treatment and made HCV elimination possible. To provide timely guidance for optimal hepatitis C management, the Taiwan Association for the Study of the Liver (TASL) established an expert panel to publish a 2-part consensus statement on the management of hepatitis C in the DAA era. After comprehensive literature review and a consensus meeting, patient-oriented, genotype-guided recommendations on hepatitis C treatment for the general and special populations have been provided based on the latest indications and scientific evidence. In the first part of this consensus, we present the epidemiology and treatment situation of hepatitis C in Taiwan, the development of DAA, pre-treatment evaluation, post sustained virologic response (SVR) monitoring, and most importantly the treatment recommendations for the general population with compensated liver disease. The second part will focus on the treatment recommendations for the special populations.

原文English
頁(從 - 到)1019-1040
頁數22
期刊Journal of the Formosan Medical Association
119
發行號6
DOIs
出版狀態Published - 6月 2020

指紋

深入研究「2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population」主題。共同形成了獨特的指紋。

引用此